{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T14:13:52Z","timestamp":1713881632455},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T00:00:00Z","timestamp":1450137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0144900","type":"journal-article","created":{"date-parts":[[2015,12,15]],"date-time":"2015-12-15T21:42:29Z","timestamp":1450215749000},"page":"e0144900","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn\u2019s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab"],"prefix":"10.1371","volume":"10","author":[{"given":"Dario","family":"Sorrentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Themistocles","family":"Dassopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Zarifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrgastro.2013.69","article-title":"State-of-the-art medical prevention of postoperative recurrence of Crohn's disease","volume":"10","author":"D Sorrentino","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2010.01.016","article-title":"Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease","volume":"8","author":"D Sorrentino","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.cgh.2013.12.035","article-title":"Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence","volume":"12","author":"M Regueiro","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/14737167.2014.950235","article-title":"The cost-effectiveness of infliximab in Crohn's disease","volume":"14","author":"C Smart","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/01.MIB.0000442680.47427.bf","article-title":"Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?","volume":"20","author":"D Sorrentino","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.crohns.2013.04.013","article-title":"When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel","volume":"7","author":"V Pittet","year":"2013","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1586\/17474124.2013.814933","article-title":"The great debate: stopping immunomodulators and biologics in Crohn's disease patients in remission","volume":"7","author":"JG Hashash","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S-450","DOI":"10.1016\/S0016-5085(14)61615-2","article-title":"High infliximab trough levels are associated with impaired quality of life in IBD patients in clinical and biochemical remission on maintenance infliximab therapy","volume":"146","author":"M Lowenberg","year":"2014","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/ibd.23016","article-title":"Stopping infliximab in Crohn\u2019s disease: still an ongoing STORI","volume":"18","author":"L Peyrin-Biroulet","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"E Louis","year":"2012","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1365-2036.2010.04446.x","article-title":"Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort","volume":"32","author":"AW Waugh","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/apt.12733","article-title":"A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease","volume":"39","author":"BG Levesque","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MIB.0000436951.80898.6d","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"S O'Meara","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"KS Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"I Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"N Vande Casteele","year":"2015","journal-title":"Gut"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"WR Best","year":"1976","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.25.6.665","article-title":"Natural history of recurrent Crohn\u2019s disease at the ileocolonic anastomosis after curative surgery","volume":"25","author":"P Rutgeerts","year":"1984","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","volume":"382","author":"SL Wang","year":"2012","journal-title":"J Immunol Methods"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review","volume":"15","author":"A Cassinotti","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient","volume":"108","author":"N Vande Casteele","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ajg.2014.106","article-title":"Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial","volume":"10","author":"C Steenholdt","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00535-013-0829-7","article-title":"Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment","volume":"49","author":"H Imaeda","year":"2014","journal-title":"J Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"C Steenholdt","year":"2014","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"BP Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/gut.2006.115980","article-title":"Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?","volume":"56","author":"SB Hanauer","year":"2007","journal-title":"Gut"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0144900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T14:36:25Z","timestamp":1567434985000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0144900"}},"subtitle":[],"editor":[{"given":"Fabio","family":"Cominelli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,15]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0144900","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,15]]}}}